| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (2MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-758761
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.75876
Zusammenfassung
In adaptive clinical trials, the conventional end-of-trial point estimate of a treatment effect is prone to bias, that is, a systematic tendency to deviate from its true value. As stated in recent FDA guidance on adaptive designs, it is desirable to report estimates of treatment effects that reduce or remove this bias. However, it may be unclear which of the available estimators are preferable, ...

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

Downloadstatistik